参考文献/References:
[1] 王 鹏，张剑宁，陈金辉，等. 存活蛋白对贝伐珠单抗治疗的胶质瘤细胞增殖及侵袭能力的影响[J]. 中华神经医学杂志，2017，16（6）：553-558.
[2] 王琦雪，赵 凯，康春生. 胶质母细胞瘤中的分子标记物和靶向治疗的研究进展[J]. 中华神经医学杂志，2019，18 （6）：629-633.
[3] 黎 苏，霍 虹，刘广宣，等. 贝伐珠单抗应用分析与合理性评价[J]. 中国医院药学杂志，2017，37（9）：855-858.
[4] Friedman S, Prados D, Wen Y, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblas- toma [J]. J Clin Oncol, 2009, 27(28): 4733-4740.
[5] Lai A, Tran A, Nghiemphu PL, et al. Phase Ⅱ study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma ultiforme [J]. J Clin Oncol, 2011, 29(2): 142-148.
[6] Gilbert R, Dignam J, Armstrong S, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma [J]. N Engl J Med, 2014, 370(8): 699-708.
[7] Taal W, Oosterkamp HM, Walenkamp AM, et al. Single- agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial [J]. Lancet Oncol, 2014, 15(9): 943-953.
[8] Field M, Simes J, Nowak K, et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma [J]. Neuro Oncol, 2015, 17(11): 1504-1513.
[9] Herrlinger U, Schafer N, Steinbach P, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: The Randomized GLARIUS Trial [J]. J Clin Oncol, 2016, 34(14): 1611-1619.
[10] Wick W, Chinot O L, Bendszus M, et al. Evaluation of pseu- doprogression rates and tumor progression patterns in a phase Ⅲ trial of bevacizumab plus radiotherapy/temozolo- mide for newly diagnosed glioblastoma [J]. Neuro Oncol, 2016, 18(10): 1434-1441.
[11] Wick W, Gorlia T, Bendszus M, et al. Lomustine and beva- cizumab in progressive glioblastoma [J]. N Engl J Med, 2017, 377(20): 1954-1963.
[12] Du C, Ren J, Zhang R, et al. Effect of bevacizumab plus temozolomide-radiotherapy for newly diagnosed glioblas- toma with different MGMT methylation status: a meta- analysis of clinical trials [J]. Med Sci Monitor, 2016; 22: 3486-3492.
[13] Fu P, He YS, Huang Q, et al. Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta- analysis of clinical trials [J]. Mol Clin Oncol, 2016; 4: 833- 838.
[14] 张 超，屈茹楠，缪 玮，等. 贝伐珠单抗临床应用的合理性及安全性评价[J]. 中国新药杂志，2017，26（17）： 127-132.
[15] 沈 倩，周 磊，尧小龙，等. 胶质母细胞瘤难治性放化疗脑水肿贝伐珠单抗联合替莫唑胺治疗临床观察[J]. 中华肿瘤防治杂志，2019，24（15）：1115-1118.
[16] Furuta T, Nakada M, Misaki K, et al. Molecular analysis of a recurrent glioblastoma treated with bevacizumab [J]. Brain Tumor Pathol, 2014, 31: 32-39.
相似文献/References:
[1]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(02):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(02):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[3]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(02):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[4]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(02):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[5]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(02):69.
[6]郑锐哲 姜秀峰 陈二涛 孙兆良 冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[7]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(02):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[8]殷安安 陆 南 贺亚龙 章 翔 刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[9]杨雅婷 李 晖.AEBP1在胶质母细胞瘤中的表达及临床意义[J].中国临床神经外科杂志,2020,(08):521.[doi:10.13798/j.issn.1009-153X.2020.08.008]
YANG Ya-ting,LI Hui..Expression of AEBP1 in human glioblastoma tissues and its clinical significance[J].,2020,(02):521.[doi:10.13798/j.issn.1009-153X.2020.08.008]
[10]张春雨 叶立果 王 龙 袁凡恩 彭泽生 陶 野 陈谦学 田道锋.胶质母细胞瘤驱动基因相关的竞争性内源RNA调控网络[J].中国临床神经外科杂志,2020,(09):607.[doi:10.13798/j.issn.1009-153X.2020.09.010]
ZHANG Chun-yu,YE Li-guo,WANG Long,et al.Competing endogenous RNA regulatory network related to glioblastoma driver genes[J].,2020,(02):607.[doi:10.13798/j.issn.1009-153X.2020.09.010]
[11]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]